The Best Time to Take Migraine Medication? It Depends on the Treatment

Why early treatment matters for some options, while others may still work later in an attack

Most people living with migraine know the question: “Should I take my medication now, or wait and see?”

Nearly half of people in one study said they often delayed taking their acute migraine medication. The most common reasons were wanting to make sure it was really a migraine attack and wanting to save medication for more severe pain.[1]

So, does waiting change how well your medication works?

It can, but the answer depends on the treatment.

For many acute migraine medications, treating while pain is still mild is recommended.[6] For some, including triptans, research shows a clear advantage to treating earlier [2][3]. But not every treatment appears to have the same timing window. Dihydroergotamine (DHE), for example, may remain effective later in an established attack.[4]

Understanding that difference can help you have a more useful conversation with your healthcare professional about whether your treatment fits the way your attacks actually unfold.

First, two different questions about “timing”

When we talk about medication timing, it is easy to mix up two different things:

1. When during the migraine attack you take the medication
For example, while pain is still mild versus several hours into the attack.

2. How long the medication takes to provide relief after you take it
This is often called the medication’s onset of action.

They are not the same thing.

A medication may work quickly once taken but have better outcomes when used earlier in an attack. Another may take longer to reach its full effect but remain useful even when the attack is already well established.

That distinction becomes particularly important when comparing treatments such as triptans and DHE.

Why can treatment timing matter during an attack?

A migraine attack is not necessarily biologically identical from beginning to end.

As an attack progresses, pain pathways in the nervous system can become increasingly responsive. This process is known as central sensitization.

One clinical sign of this is cutaneous allodynia, where normally painless sensations start to hurt. Brushing your hair, wearing glasses, touching your scalp, or resting your head on a pillow may suddenly feel uncomfortable or painful.[3]

Why does this matter?

Because the development of allodynia can affect how well some acute migraine treatments work.

But that effect is not identical across all medications.

Triptans: why treating while pain is mild can matter

Triptans are migraine-specific medications that act mainly on serotonin 5-HT1B and 5-HT1D receptors.

For this class, there is substantial evidence supporting treatment while migraine pain is still mild.

In one analysis, treating with the triptan almotriptan while pain was mild resulted in 84% of attacks being pain-free at two hours, compared with 53% when treatment was delayed until pain was moderate or severe.[2]

Research on allodynia helps explain why timing may matter.

In another study, triptan treatment resulted in pain freedom in 93% of attacks without established allodynia, compared with only 15% of attacks in which allodynia was already present.[3]

Interestingly, the key factor was not simply the number of hours that had passed. Triptans were much more successful when used before allodynia had developed, whether the dose was taken relatively early or later in the attack.[3]

So for triptans, the practical message is not simply “watch the clock.”

It is that treating while pain is still mild and before central sensitization becomes established may improve the chance of complete relief.

Always follow the instructions for your specific medication and the treatment plan agreed with your healthcare professional.

DHE: why the treatment window may be broader

Dihydroergotamine, or DHE, is another migraine-specific acute treatment, but its pharmacology differs from that of triptans.

DHE acts at 5-HT1B and 5-HT1D receptors too, but it interacts with a broader range of serotonin, adrenergic and dopaminergic receptors.[4]

It also remains bound to some serotonin receptors considerably longer than sumatriptan. These pharmacological characteristics are thought to contribute to DHE’s relatively long-lasting effects.[4][5]

That difference may also matter when an attack is already established.

A review of systemic DHE found evidence of efficacy when it was administered early in an attack as well as later, including up to eight hours after migraine onset. DHE has also been reported as useful in people experiencing allodynia and in recurrent or prolonged migraine attacks.[4]

This does not mean timing is irrelevant when using DHE, or that every DHE formulation behaves identically. Formulation, route of administration, dose and individual response still matter.

But it does mean the simple rule “if you did not treat early, you missed your chance” does not apply equally to every acute migraine treatment.

What about central sensitization?

Preclinical research discussed in the DHE literature found that DHE could reverse established central sensitization in an animal model, whereas a triptan could not.[4]

That finding may help explain some of the differences observed between the treatments, but it is important not to overinterpret it: reversal of established central sensitization has not been proven in humans in the same way.

The human evidence is better described as showing that DHE may retain efficacy later in an attack and in people experiencing allodynia.[4]

Faster relief and longer-lasting relief are also different

Another reason migraine treatments cannot be ranked using a single measure is that speed and durability are not the same thing.

Some triptans can provide relatively fast initial relief, particularly certain non-oral formulations.

DHE can have a slower initial antimigraine effect depending on the formulation, but its receptor-binding characteristics may contribute to a longer-lasting effect.[5]

A review comparing DHE clinical trials found that subcutaneous sumatriptan produced greater headache relief than subcutaneous DHE during the first two hours, but the treatments were similarly effective after three hours.[5]

So asking only “Which works faster?” misses part of the picture.

Other useful questions include:

• Does the treatment get you fully pain-free?
• Does the relief last?
• Does your headache return?
• Does it work if you cannot treat immediately?
• Do you need another dose or rescue medication?
• Does the formulation work for you during nausea or vomiting?

A treatment that fits you well needs to fit the whole attack, not just one time point.

What about other acute migraine treatments?

Triptans and DHE illustrate why we should be careful about applying one timing rule to every medication.

Other acute options include over-the-counter pain relievers, NSAIDs, gepants, ditans, antiemetics and neuromodulation devices. Each has its own mechanism, dosing instructions, safety considerations and evidence.[6]

The American Headache Society includes treating early among the general principles of acute migraine treatment, while also recommending that treatment choice account for efficacy, safety, tolerability, route of administration and the individual patient.[6]

So the general principle remains useful: for many acute treatments, do not unnecessarily wait for pain to become severe.

But the more precise question is:

When does my specific treatment work best?

That answer may differ by medication.

Why effective acute treatment can matter over time

Finding an acute treatment that works reliably is important for getting through individual attacks, but research also suggests it may matter over the longer term.

Cutaneous allodynia, a marker of central sensitization, has been associated with an increase in migraine days over time.[7]

Separately, ineffective acute migraine treatment has been associated with a greater likelihood of progressing from episodic to chronic migraine. In one large observational study, 1.9% of people with maximum acute-treatment efficacy developed chronic migraine over the following year, compared with 6.8% of those reporting very poor treatment efficacy.[8]

There is an important limitation here.

These studies show associations. They do not prove that taking one medication late, experiencing one episode of allodynia, or having one poorly treated attack causes chronic migraine. The authors of the acute-treatment study specifically note that reverse causality cannot be excluded.[8]

What they do suggest is that recurring allodynia and consistently inadequate acute treatment are worth discussing with your healthcare professional rather than simply accepting them as part of migraine.

Is your treatment timing working for you?

During an attack, it can be surprisingly difficult to remember exactly what happened and when.

Tracking can help you see the relationship between when you treated and what happened afterward.

For each attack, consider recording:

• When the attack began
• How intense the pain was when you treated
• Whether symptoms of allodynia were present
• What medication and formulation you used
• When you took it
• When relief began
• Whether you became completely pain-free
• Whether symptoms or pain returned
• Whether you needed more than one dose for complete relief
• Any side effects

Migraine Buddy keeps these details together so you can look for patterns across several attacks.

For example, you might notice that your triptan works reliably when you take it while pain is still mild but gives incomplete relief once scalp sensitivity has developed.

Or you may find that you regularly cannot treat until your migraine is already well established.

Those patterns are useful information.

If you often need multiple doses, experience incomplete or short-lived relief, or your medication does not seem to fit the point in the attack when you are realistically able to take it, consider discussing other treatment options or formulations with your healthcare professional.

The bottom line

There is good evidence supporting early acute treatment of migraine, and for some medications, particularly triptans, taking treatment while pain is still mild can substantially improve outcomes.[2][3]

But “sooner is always better” is too simple to apply to every migraine medication.

Different treatments have different pharmacology and different treatment windows. DHE is an important example: research suggests it may retain efficacy later in an established attack, including in people experiencing allodynia.[4]

The goal is not to beat an arbitrary clock.

It is to understand when your specific treatment is designed to work best, use it according to its instructions, and find a treatment plan that matches how your migraine attacks happen in real life.

Tracking when you treat and what happens afterward can give you and your healthcare professional better information to make that plan work.

Sources

[1] Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005;45(5):538–545.
https://pubmed.ncbi.nlm.nih.gov/15953272/

[2] Pascual J. Clinical benefits of early triptan therapy for migraine. Headache. 2002;42 Suppl 1:10–17.
https://pubmed.ncbi.nlm.nih.gov/11966859/

[3] Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Annals of Neurology. 2004;55(1):19–26.
https://pubmed.ncbi.nlm.nih.gov/14705108/

[4] Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) – Then and Now: A Narrative Review. Headache. 2020;60(1):40–57.
https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13700

[5] Tfelt-Hansen PC. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review. Cephalalgia. 2013;33(13):1122–1131.
https://pubmed.ncbi.nlm.nih.gov/23588793/

[6] American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1–18.
https://pubmed.ncbi.nlm.nih.gov/30536394/

[7] Louter MA, Bosker JE, van Oosterhout WPJ, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(11):3489–3496.
https://pubmed.ncbi.nlm.nih.gov/24080152/

[8] Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–695.
https://pubmed.ncbi.nlm.nih.gov/25609757/